NOT FOR DISTRIBUTION, RELEASE OR REPUBLICATION, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, RELEASE OR REPUBLICATION WOULD BE UNLAWFUL.
Oslo, 24 March 2021: Reference is made to the stock exchange notice issued on 24 February 2021 where Arctic Bioscience AS (“Arctic Bioscience” or the “Company”) announced the beginning of the stabilization period following a private placement of new shares in the Company (the “Private Placement”) and admission to trading of the Company’s shares on Euronext Growth Oslo (the “Admission”).
DNB Markets, a part of DNB Bank ASA (“DNB Markets”), acting as stabilization manager has informed the Company that the stabilization period has ended. Stabilization activities has been undertaken between 24 February 2021 and 24 March 2021 (the “Stabilization Period”) and comprise a total of 1,451,612 shares in the Company, purchased at an average price of NOK 28.0717, as further set out in the attached end of stabilization notification.
As a consequence of the stabilization activities taken, DNB Markets has informed the Company that it will not exercise the greenshoe option and shall redeliver the 1,451,612 shares purchased through stabilization transactions to Capra Invest AS and Ronja Capital II AS, in accordance with the terms of the share lending agreement between the parties.
ABG Sundal Collier ASA and DNB Markets, part of DNB Bank ASA, acted as Joint Global Coordinators and Joint Bookrunners in the Private Placement and as Euronext Growth advisors in relation to the Admission (the “Managers”). Adviso advokatfirma AS and Advokatfirmaet Wiersholm AS acted as legal counsels in connection with the Private Placement and the Admission.
For further information, please contact: DNB Markets, a part of DNB Bank ASA Aksel Thue Tel: +47 23 26 81 01
This information is subject of the disclosure requirements pursuant to Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 section 6 (3).
Mobile: +47 909 98 201